Job Openings

HepaRegeniX has successfully discovered and developed several clinical drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4.


There are currently no vacancies.

HepaRegeniX GmbH
Dr. Michael Lutz
CEO / Managing Director
Phone: +49 (0)7071 7912810
Fax: +49 (0)7071 7912809

    Unsolicited application!

    Yes, apply unsolicited


    Further information on the storage, processing and transmission of personal data can also be found in the privacy policy on this website.

    If you attached large files please do not close this window until it is confirmed that you successfully sent your application´s data.